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Abstract
Background: Upregulated levels of 18-kDa translocator proteins (TSPO) and type 2 endocannabinoid receptors (CB2)
are considered to reflect different aspects of microglia-related neuroinflammatory responses in the brain. Relative to
the increase in the TSPO expression that occurs slightly later during neuroinflammation in a proinflammatory fashion,
CB2 activation is considered to relate to the neuroprotective responses that occurs predominantly at an early stage of
brain disorders. These findings, however, were deduced from studies with different animal samples under different
experimental settings. Here, we aimed to examined the differences in TSPO binding and CB2 availability at an early
stage of stroke in the same animal using positron emission tomography (PET).
Methods: We used a total of eight Sprague-Dawley rats that underwent photothrombotic stroke surgery. The binding
levels of a TSPO tracer [11C](R)PK11195 and a CB2 tracer [11C]NE40 were measured at 24 h after the surgery in the same
animal using PET in combination with immunohistochemistry for CB2 and several other markers. A morphological
inspection was also performed with X-ray computed tomography for small animals.
Results: The levels of [11C]NE40 binding potential (BPND) were significantly higher in the cerebral cortical region on the
lesion side than those on the non-lesion side, whereas no difference was found in the levels of [11C](R)PK11195 BPND
between hemispheres. The tracer influx index (R1) data were all reduced on the lesion side irrespective of tracers. This
increase in [11C]NE40 BPND was concomitant with an elevation in CB2 expression mainly within the microglia in the
peri-infarct area, as shown by immunohistochemical examinations with Iba-1, CD11b/c+, and NG2+ staining.
Conclusions: The present results provide in vivo evidence of different responses of microglia occurring in the acute state
of stroke. The use of the CB2 tracer [11C]NE40 allows us to evaluate the roles played by the neuroprotective aspect of
microglia in acute neuroinflammatory processes.
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Background
Microglia change morphologically and functionally from
their resting state to their activated state in response to
several neuroinflammatory and neurodegenerative dis-
eases. In other words, microglial activation accompanies
any damage to the brain environment. This is one rea-
son why activated microglia represent an important
marker of neuroinflammation [1]. Specifically, non-
invasive imaging of activated microglia is a useful tool to
detect in vivo neuroinflammatory disease. To date, the
first-generation translocator protein 18 kDa (TSPO)
marker [11C](R)PK11195 has been widely used as a PET
radioligand for that purpose. PET studies using
[11C](R)PK11195 have been carried out on patients with
several neuroinflammatory diseases such as Alzheimer’s
disease (AD) [2], Parkinson’s disease (PD) [3], and Hun-
tington’s disease [4]. In addition, ischemic stroke causes
direct insults to brain tissue and the immediate activa-
tion of microglia, which can also be visualized on PET
with [11C](R)PK11195 [5]. This is an experimental ad-
vantage in studies on time course changes in microglial
activation, unlike animal models for chronically devel-
oped neurodegenerative brain disorders. Specifically,
since stroke is a sudden onset disease, an early depiction
of the extent at which the brain is compromised is im-
portant for treatment to delay the disease progression.
In this context, TSPO imaging may be preferable. To
date, it is well documented that the accumulation of
[11C](R)PK11195 or the second-generation tracer
[18F]DPA714 is reported to occur relatively later after
brain injury resulting from toxin injection [6] or trau-
matic insults [7, 8].
The imaging of endocannabinoid receptor type 2 (CB2)
has recently been considered to be an alternative method
for targeting activated microglia using PET imaging. The
endocannabinoid system in the central nervous system
has been identified to provide neuroprotective effects fol-
lowing brain injury. In particular, CB2 is upregulated in
microglia during neurodegenerative and neuroinflamma-
tory diseases such as AD [9–11], multiple sclerosis [12],
PD [13] and ischemia [14–17], and is associated with
microglial activity [18]. Moreover, the administration of a
selective CB2 agonist reduced infarct volume and im-
proved motor function scores [16]. Recently, a PET tracer
that binds specifically to CB2 was developed to illustrate
CB2 availability in vivo [19]. Although it was reported that
the binding of [11C]NE40 24 h after ischemic injury using
a photochemically induced thrombosis (PIT) technique
failed to increase [20], six out of nine PET data were not
corrected for the attenuation of radioactivity, and the cor-
rection is critical for the quantification of PET data. Con-
sidering the early-developed neuroprotective role of
microglia, a failure to detect the elevation of [11C]NE40
uptake in AD patients [21] is understandable because the
activated microglia during the chronic state of neurode-
generation are considered to be acting as proinflammatory
agents [22]. Therefore, the stroke model might be suitable
for evaluating the early response of microglia because the
insult can be controlled purposefully.
In neuroinflammation, microglia are considered to play a
dual role in their function. Classically activated M1 pheno-
type microglia release proinflammatory mediators, whereas
alternatively activated M2 phenotype microglia enhance
phagocytic activity and reduce the production of inflamma-
tory mediators [23, 24]. In our previous study, we demon-
strated that neuronal damage occurred on days 1, 3, 7, and
14 after PIT using [11C](R)PK11195 [25]. The uptake peak
of [11C](R)PK11195 was found on day 7 after PIT treatment
and overlapped with the high immunoreactivity area of
microglial marker Iba1, suggesting that the uptake of
[11C](R)PK11195 reflects microglial activity. However, it is
difficult to distinguish between neurotoxic M1 and neuro-
protective M2 microglia phenotypes on PET imaging with
[11C](R)PK11195. Then, we focused on [11C]NE40, which
targets CB2, with the goal of observing neuroprotective
microglia at an acute stage of brain injury.
Therefore, the purpose of the present study was to
focus on the early phase of stroke and to elucidate the
different binding patterns of CB2 and TSPO tracers in a
very acute stage of brain insult, such as stroke, by com-
paring the levels of [11C]NE40 binding with those of
[11C](R)PK11195 binding in rats after PIT surgery. These
in vivo data were evaluated with immunohistochemistry
for CB2, TSPO, and several cell type-specific markers
after completion of the PET measurements, resulting in
cessation of the in vivo study with the same animals.
Methods
Animals
Eight 8-week-old male Sprague-Dawley rats (250–300 g)
purchased from the SLC Company (Hamamatsu, Japan)
were used in this study. They were housed in cages with
free access to food and water. All animal protocols and
the following experiments were approved by the Ethics
Committees of the Central Research Laboratory at Ha-
mamatsu Photonics and Hamamatsu University School
of Medicine. In addition, all applicable institutional and/
or national guidelines for the care and use of animals
were followed.
The PIT procedure was performed as reported previ-
ously [26]. Briefly, the rats were anesthetized and main-
tained with 2% halothane in a mixture of 70% room air
and 30% O2 throughout the following procedure. After
the insertion of an infusion line into the tail vein, the
scalp and temporal muscle were flipped, and then a sub-
temporal craniotomy was performed. The main trunk of
the left middle cerebral artery (MCA) was observed
through the dura mater under an operating microscope
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through a window that was anterior to the foramen of
the mandibular nerve. After the intravenous infusion of
20 mg/kg of rose bengal (Wako Pure Chemical Industry,
Osaka, Japan), photoillumination was performed utiliz-
ing a green light at 540 nm (model L4887, Hamamatsu
Photonics, Hamamatsu, Japan), which was delivered to
the MCA through the dura mater for 10 min using a 3-
mm optic fiber placed onto the window within the skull
base. After confirming thrombotic occlusion of the
MCA, the incision was closed. The animals were then
allowed to awake from anesthesia and were returned to
their cages.
PET measurements
We utilized a high-resolution animal PET scanner (SHR-
38000, Hamamatsu Photonics, Japan) under an axial field
of view (FOV) of 330 mm, a transaxial FOV of 108 mm,
and a transaxial spatial resolution of 2.3 mm in the center.
Eight animals were scanned twice a day using PET with
[11C](R)PK11195 and [11C]NE40 beginning 24 h after PIT.
The interval between the two scans was set to 2 h, and the
order of the scans was counterbalanced. The animals were
anesthetized using an initial dose of chloral hydrate
(400 mg/kg, i.p.) followed by a continuous infusion of
chloral hydrate (100 mg/kg/h, i.v.) during the entire im-
aging experiment. They were placed in the prone position
on a fixation plate and then set within the gantry hole of
the PET scanner. After a 15-min transmission scan utilizing
an external 68Ge/68Ga rod source (67 MBq) for attenuation
correction, a serial emission scan that lasted for 60 min was
performed immediately following each tracer injection of
[11C](R)PK11195 or [11C]NE40 at a dose of 48 MBq/kg;
tracers were injected intravenously through the cannula
that was inserted into the tail vein. The specific activity of
each tracer used was above 50 GBq/μmol. No arterial sam-
pling was conducted. The PET data were reconstructed
using 3D DRAMA (iteration 2, gamma 0.1) with a Gauss
filter of 1.0 mm in full width at half maximum (FWHM),
yielding a voxel size of 0.65 × 0.65 × 1.0167 mm for the re-
constructed image. To obtain the anatomical information,
X-CT scans were performed immediately following PET
measurement using a ClairvivoCT (Shimadzu Corporation,
Kyoto, Japan).
Data analysis and statistics
Using an image analysis software (PMOD, version 3.1;
PMOD Technologies Ltd, Zurich, Switzerland), we esti-
mated the levels of BPND (an availability of TSPO and CB2)
and R1 (a tracer influx index according to blood flow: a ra-
tio of K1/K′1, or an influx in target of interest/an influx in
reference of interest) for [11C](R)PK11195 and [11C]NE40
based on a simplified reference tissue model [27, 28] and
then created the parametric brain images of BPND and R1
(a tracer uptake index). During this process, the time-
activity curve from the bilateral cerebellar cortex was used
as a reference input function because the infratentorial
brain region might be less affected by the MCA occlusion
event; however, functional connection emerging as diaschi-
sis could be a possibility of the confounding factor. The se-
lection of the intact contralateral cortical region as a
reference region as conducted elsewhere [20] seems inad-
equate because the numbers of the CD11b+/CD3+ cells
(for microglia) were comparable in ischemia-affected and
non-affected hemispheres 24 h after stroke [29].
As described elsewhere [30, 31], the elliptical regions
of interest (ROIs), ranging from 12 to 24 mm2 wide,
were symmetrically placed in the bilateral brain regions
covering the peri-infarct area mainly in the frontal and
parietal cortices by referring to the X-CT images, on
which the coronal slices of the frontal and parietal corti-
ces were determined according to the Paxinos rat brain
stereotactic atlas [32] (see Additional file 1: Figure S1).
Student’s t test statistics were used to compare the
conditions and the significance level was set at p < 0.05
with a correction for multiple comparisons because mul-
tiple loci were chosen.
Immunohistochemistry
The rats were anesthetized with chloral hydrate
(400 mg/kg) and then transcardially perfused with saline
followed by 4% paraformaldehyde (PFA) (pH 7.4). The
brains were removed, post-fixed in 4% PFA, and
immersed in cryoprotectant solution (30% sucrose in
0.1 M phosphate buffer) until the tissue sank. Tissues
were frozen in dry ice and stored at −80 °C until they
were used. Twenty-micrometer frozen coronal sections
were cut using a cryostat. The slides were blocked with
5% goat serum in PBS containing 0.1% Triton X-100 for
1 h at room temperature (RT) and then incubated with
primary antibodies for 2 h at RT. After being washed,
the slides were then incubated for 2 h at RT with sec-
ondary antibodies. The following primary antibodies
were used in this study: mouse anti-GFAP (1:500, Milli-
pore), rabbit anti-Iba1 (1:1000, Wako), mouse anti-
CD11b/c (1:500, DB Pharmingen), mouse anti-NG2
(1:200, Millipore), rabbit anti-cannabinoid receptor 2
(1:100, Abcam), and rabbit anti-rat TSPO (1:200, Bio-
byt). The following secondary antibodies were used in
this study: Alexa Fluor 488 anti-rabbit-IgG and Alexa
Fluor 594 anti-mouse-IgG (1:500, Invitrogen).
Results
PET findings
The Student’s t test showed a significantly higher level of
[11C]NE40 BPND in the affected regions of the frontal cor-
tex (t = 3.54, p < 0.05 corrected for multiple comparisons)
and parietal cortex on the lesion side (t = 3.21, p < 0.05 cor-
rected) than [11C](R)PK11195 BPND (Table 1, Fig. 1a, b). In
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contrast, the R1 value that reflects the degree of tracer in-
flux depending on regional blood flow was frequently ob-
served to be low in the MCA territory, regardless of the
tracer used (Fig. 1c, d), suggesting that the influxes of these
two different tracers might be equally damaged in this ex-
perimental setting. An additional examination using tracer-
summation PET images (standardized uptake value, SUV)
failed to show this significance although the similar trend
was found (Additional file 2: Figure S2).
As shown in Fig. 2, higher uptake of [11C]NE40 was ob-
served in the peri-infarct region (penumbra, arrow) than
the [11C](R)PK11195. Although the difference in time
course of the tracer uptake (the tissue time-activity curve,
TAC) was small between [11C]NE40 and [11C](R)PK11195,
there was a gradual increase in [11C]NE40 TAC on the
ipsilateral (infarct) side later during the scan, while no dif-
ference was observed in [11C](R)PK11195 TACs on either
side.
Immunohistochemical findings
The brain section images revealed that large ischemic
lesions occurred from the striatum to the cortical re-
gion in our experimental model. Within the infarct
core, only cell debris was observed (Additional file 3:
Figure S3). As shown in Additional file 3: Figure S3
and Fig. 3, Iba-1-positive cell and CD11b/c+ cell re-
gions were predominantly found within the peri-
infarct region, while GFAP-positive astrocytes were
found to be scattered throughout the brain.
Co-staining for CB2 and the microglial marker
CD11b/c showed that CD11b/c+ microglia in the
contralateral (non-lesion) area were in their resting state
with ramified processes, while they were negative for
CB2 on day 1 after PIT treatment (Fig. 3). It appeared
that microglial processes surrounded the CB2+ cells. In
the peri-infarct area, some CD11b/c+ cells were co-
labeled with CB2; their form exhibited a round shape
(Fig. 3, arrowhead). Co-staining for TSPO and CD11b/c
shows that microglia did not express TSPO (Fig. 3).
Table 1 Differences in the levels of BPND and RI values
Region [11C]NE40 [11C](R)PK11195
Lesion Contralateral Lesion Contralateral
BPND Frontal 1.79 ± 0.99* 0.51 ± 0.48 1.07 ± 1.20 1.47 ± 0.90
Parietal 1.27 ± 0.77* 0.63 ± 0.51 0.60 ± 0.56 0.73 ± 0.58
R1 Frontal 0.73 ± 0.74 0.87 ± 0.31 0.68 ± 0.80 0.80 ± 0.34
Parietal 0.68 ± 0.27 1.02 ± 0.30 0.47 ± 0.31 0.73 ± 0.27
*p < 0.05 vs contralateral (non-lesion) side
Fig. 1 The levels of BPND (a, b) and R1 (c, d) in each brain region in [
11C]NE40 and [11C](R)PK11195 studies, respectively. Only BPND of [
11C]NE40
was significantly higher in the affected cortical regions compared to the intact regions (*p < 0.05)
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TSPO was negative in all areas. Because no GFAP-
positive astrocytes were co-labeled with CB2, GFAP+
cells were unlikely to be associated with CB2+ cells
(Fig. 4).
Because NG2 (neural/glial antigen 2) was reported
to be highly expressed at an early state after brain in-
jury [33] and in the activated microglia and infiltrated
macrophages in brain insults [34–37], we also per-
formed co-staining for CB2 and NG2 to determine
whether CB2 in the peri-infarct area was expressed
by activated NG2+ cells. The NG2 signal was very
strong in regions adjacent to the infarct area and
some NG2-positive cells were co-labeled with CB2
(Fig. 4). Notably, CB2+/NG2+ cells were round in
shape (Fig. 4, arrow head) and CB2−/NG2+ cells ex-
hibited a ramified form with thin processes (Fig. 4,
arrow).
Co-staining with CB2 and the neural marker NeuN
showed that some NeuN+ cells in the contra- and ip-
silateral cortices were weakly co-labeled with CB2
(Fig. 5). However, in the peri-infarct area, no NeuN+
cells were co-labeled with CB2. Therefore, the uptake
of [11C]NE40 in the contralateral cortex might reflect
some degree of its binding to CB2 on neurons.
Discussion
Microglial activation detection using the CB2 tracer
We found an increase in [11C]NE40 binding and ele-
vated CB2 availability specifically in the peri-infarct area
at an early stage after ischemic injury induced by the
PIT method. This finding was consistent with our im-
munohistochemical results that showed co-localization
of CD11b/c+ and CB2-positive cells exhibiting microglia
with a round shape, suggesting that some CD11b/c+
cells expressed CB2 in regions adjacent to the infarct
area. This immunohistochemical finding is also in line
with the previous observation that a number of CD11b
+/CD3+ cells (for microglia) were found in ischemia-
affected areas 24 h after stroke [29]. A previous report
suggested that CB2 can be detected in the “responsive”
and “primed” states but not in the “resting” state of
microglia in vitro [38]. Thus, microglia on day 1 after
PIT treatment might be at an early stage in the inflam-
matory process, being in either the “responsive” or
“primed” state in vivo. In contrast, the binding of
[11C](R)PK11195 was not co-localized in areas with high
[11C]NE40 binding. Because TSPO tracers such as
[11C](R)PK11195 are considered to be PET probes of de-
layed microglial activation as shown in literature [22],
Fig. 2 Coronal parametric images of BPND, R1, and SUV (standardized uptake value) superimposed on X-CT images in [
11C]NE40 and [11C](R)PK11195
studies. A SUV image was generated as a summation of tracer uptake during 40–60 min post-injection. The arrows indicate the peri-infarct region
(penumbra). Mean tissue time-activity curves with standard deviations of each tracer on both frontal cortices are shown in different panels. Ipsilateral,
lesion side; contralateral, non-lesion side
Hosoya et al. Journal of Neuroinflammation  (2017) 14:69 Page 5 of 9
Fig. 3 Double-immunostaining for CB2 and CD11b/c in the contralateral (non-lesion) (a) and the peri-infarct (b) areas and for TSPO in the contralateral
(c) and peri-infarct (d) areas on day 1 after PIT treatment. Several microglia were co-stained for CB2 and CB11b/c (arrowhead). Scale bar, 25 μm
Fig. 4 Double-immunostaining for CB2 (green) and GFAP (red) in the peri-infarct area (a). NG2+/CB2+ cells were round (arrowhead) and NG2
+/CB2− cells were in a ramified form (arrow). b Double-immunostaining for CB2 (green) and NG2 (red) in the peri-infarct area on day 1 post PIT
treatment. Scale bar, 25 μm
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the presence of [11C]NE40 uptake along with a lack of
[11C](R)PK11195 uptake suggests that CB2 may be more
implicated than TSPO during the early-phase activation
of microglia in the post-stroke brain region.
Differences in binding of TSPO and CB2 tracers
In our previous study, we utilized [11C](R)PK11195 and
studied its uptake at several time points in the PIT
model; furthermore, by utilizing immunostaining for
Iba1, high [11C](R)PK11195-uptake areas appeared to
correspond to high microglial activity areas on day 7
after PIT treatment [25]. In this study, we demonstrated
that [11C]NE40 is a suitable target for a PET tracer de-
tecting neuroinflammation developed soon after brain
ischemic insult because the uptake of [11C]NE40 is
higher than that of [11C](R)PK11195 1 day after PIT
treatment. To date, [11C](R)PK11195 has primarily been
used for the imaging of inflammatory conditions such as
neurodegenerative diseases. In the chronic stage of in-
flammation [6], neurotoxic M1 phenotype microglia are
dominant and the TSPO tracer [11C](R)PK11195 reflects
inflammatory rather than anti-inflammatory microglial
activity [22]. To support this contention, we recently
showed an elevation in the second-generation TSPO
tracer [11C]DPA713 for illustrating chronically activated
microglia under inflammatory circumstances [39].
Role of microglia in activation
Some studies have indicated that microglial CB2 is neu-
roprotective both in vivo and in vitro. The administra-
tion of the CB2 agonist JWH-133 in an ischemic rat
brain model reduced ischemic volume, promoted the
production of anti-inflammatory mediators, and sup-
pressed the release of inflammatory mediators and Iba1
expression in microglia [15]. In an in vitro experiment,
the administration of anandamide (a kind of endocanna-
binoids) to lipopolysaccharide-treated microglia reduced
the activation of M1 phenotype microglia and elevated
anti-inflammatory factors [40]. Overexpression of CB2
causes mice to have resistance to depression after stress
[41] and intraperitoneal administration of a CB2 agonist
can ameliorate anxiolytic effects [42]. Thus, the present
PET data that show a higher accumulation of [11C]NE40
and lower binding of [11C](R)PK11195 at an early stage
after PIT-induced stroke indicate possibly different roles
of microglia in terms of neuroprotective or neuroinflam-
matory content during early brain injury.
Immunostaining and PET findings
The current immunohistological study showed that the
CB2+ cells were surrounded by microglial processes and
some CD11b/c+ cells with a round morphology were
co-labeled with CB2 in the peri-infarct area. In addition,
CB2-positive cells were weakly co-labeled with NeuN in
the contralateral cortex and CB2+/NeuN+ neurons were
surrounded by CB2+ cell processes. The latter finding
might induce a slight upregulation of [11C]NE40 on the
contralateral side, which might explain why no GFAP+
cells were co-labeled with CB2. The immunostaining
finding that CB2-colabelled NG2+ cells were found to
be round in shape suggested that they were monocytes
and played a protective role [43]. In contrast, NG2+ cells
without co-labeling with CB2 were thought to be oligo-
dendrocyte precursor cells insensitive to CB2. It appears
that astrocytes are not associated with CB2 1 day after
PIT treatment, even though GFAP+ cells were co-
labeled with CB2 on day 3 after ischemic injury [44].
Day 1 after injury may be too early for astrocytes to re-
spond because the activation of astrocytes is considered
to occur at a late stage of the inflammatory process. Al-
though the TSPO tracer [11C](R)-PK11195 is believed to
bind not only to activated microglia but also to activated
astrocytes, either [11C]NE40 or [11C](R)PK11195 may
not have captured astrocyte activation during the early
stages of injury in the current experiment. Incompatible
with the low level of [11C](R)-PK11195 binding, the
TSPO immunohistochemical staining exhibited a negli-
gible level of TSPO expression in microglia in the ipsi-
lateral lesion area.
Limitations
First, we measured changes in the uptake of both
[11C]NE40 and [11C](R)PK11195 24 h after surgery.
These data cannot elucidate the timing of the state
Fig. 5 Double-immunostaining for CB2 and NeuN in the contralateral cortex. Some NeuN+ cells were weakly co-labeled with CB2. Scale
bar, 25 μm
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switch, dominancy, protective activity, or inflammatory
processes of microglia. Different methods for acute
stroke (transient or permanent ischemia) would generate
different outcomes in the ischemic region with regard to
inflammatory substances and cells as shown previously
[29, 44]. According to these reports, the present PIT
technique, one of the permanent stroke models, would
yield less damage than transient, reperfusion model. As
for microglia, not number but morphology of microglia
was reportedly changed 1 day after permanent stroke
[44]. Despite these findings, further study is needed to
address changes in time course of inflammatory events
after stroke. Second, because the cerebellum was chosen
as the reference region to calculate BPND in this study,
vascular injury may affect each region of the brain on
the theory of diaschisis. However, the cerebellar PET
counts were averaged between both sides in this study to
minimize these possible diaschisis effects. Therefore, the
estimated BPND values could reflect tissue tracer binding
at target regions. Third, because the spatial resolution of
the PET scanner used was relatively large (2.3 mm),
there might be an effect of partial volume on the results.
To reduce this effect, we tried to set ROIs that measured
areas twice as large as the FWHM of the scanner, or we
may choose autoradiography instead of PET although
the parameters changing in the same animal cannot be
obtained in autoradiography.
Conclusions
The present increase in [11C]NE40 binding, but not
[11C](R)PK11195 binding concomitant with a higher
CB2 immunochemical expression within the microglia
over the peri-infarct region early after PIT injury, indi-
cates that acutely activated microglia in early-stage is-
chemic stroke might be involved in the neuroprotective
process of neuroinflammation. While a recent new CB2
tracer [11C]A836339 has been reported to exceed the
sensitivity of [11C]NE40 to bind to CB2 under the
chronic state of neurodegeneration in vivo [9], the
present result suggests that [11C]NE40 might be ad-
equate for depicting activated microglia at a very early
stage of brain disorders.
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Additional file 1: Figure S1. CT images and regions of interest. Frontal,
−2 mm from the olfactory-frontal cortex junction (nearly 3 mm from the
bregma). Parietal, −6 mm from the junction (nearly −1 mm from the bregma).
Blue, lesion side; light blue, contralateral (non-lesion) side. (JPG 68 kb)
Additional file 2: Figure S2. The levels of SUV in each brain region. No
significant difference was found in either [11C]NE40 or [11C](R)PK11195
SUV levels. (JPG 100 kb)
Additional file 3: Figure S3. Immunohistochemical results one day
after photochemically induced thrombosis (PIT). Iba-1- and GFAP-positive
regions are scattered around the infarct core. (JPG 248 kb)
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